Rekombinanter SIGLEC7 Antikörper (PE)
Kurzübersicht für Rekombinanter SIGLEC7 Antikörper (PE) (ABIN7867430)
Target
Alle SIGLEC7 Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- PE-conjugated Anti-SIGLEC7 antibody(DMC475), IgG1 Chimeric mAb
-
Aufreinigung
- Purified from cell culture supernatant by affinity chromatography
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Flow Cyt 1:100
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- Liquid PBS with 0.05 % Proclin300, 1 % BSA
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store at 2°C-8°C for 6 months
-
Haltbarkeit
- 6 months
-
-
- SIGLEC7 (Sialic Acid Binding Ig-Like Lectin 7 (SIGLEC7))
-
Andere Bezeichnung
- SIGLEC7
-
Hintergrund
-
Synonyms: AIRM-1, AIRM1, CD328, CDw328, D-siglec, p75, p75:AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2
Target Background: Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- and alpha-2,6-linked sialic acid. Also binds disialogangliosides (disialogalactosyl globoside, disialyl lactotetraosylceramide and disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Mediates inhibition of natural killer cells cytotoxicity. May play a role in hemopoiesis. Inhibits differentiation of CD34 cell precursors towards myelomonocytic cell lineage and proliferation of leukemic myeloid cells (in vitro).[UniProtKB:Swiss-Prot Function]
-
UniProt
- Q9Y286
Target
-